9.20
-0.06
(-0.65%)
At close: April 17 at 4:00:01 PM EDT
9.35
+0.15
+(1.63%)
After hours: April 17 at 7:24:07 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 9 | 7 |
| Avg. Estimate | -1.03 | -0.87 | -3.58 | -3.92 |
| Low Estimate | -1.16 | -1.19 | -4.7 | -5.75 |
| High Estimate | -0.57 | -0.21 | -2.27 | -1.6 |
| Year Ago EPS | -1.34 | 1.22 | -2.27 | -3.58 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 9 | 7 |
| Avg. Estimate | 8.18M | 15.34M | 50.6M | 100.24M |
| Low Estimate | -- | -- | -- | 5M |
| High Estimate | 37.5M | 51.1M | 150M | 215.28M |
| Year Ago Sales | 50k | 132.01M | 135.16M | 50.6M |
| Sales Growth (year/est) | 16,257.14% | -88.38% | -62.56% | 98.11% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.22 | -1.03 | -1.18 | -1.04 |
| EPS Actual | -1.34 | 1.22 | -1.1 | -1.08 |
| Difference | -0.12 | 2.26 | 0.08 | -0.04 |
| Surprise % | -9.99% | 217.87% | 6.58% | -3.74% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -1.03 | -0.87 | -3.58 | -3.92 |
| 7 Days Ago | -1.03 | -0.87 | -3.58 | -3.92 |
| 30 Days Ago | -1.23 | -0.93 | -3.58 | -3.92 |
| 60 Days Ago | -1.23 | -0.93 | -4.09 | -3.34 |
| 90 Days Ago | -1.28 | -1.29 | -4.09 | -3.61 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | -- | 3 | 1 |
| Up Last 30 Days | 2 | 2 | 4 | 1 |
| Down Last 7 Days | -- | 1 | 1 | 2 |
| Down Last 30 Days | -- | -- | 1 | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| PRTA | 23.01% | -171.04% | -57.90% | -9.40% |
| S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight to Overweight | 2/26/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/24/2025 |
| Maintains | RBC Capital: Sector Perform to Sector Perform | 2/21/2025 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 2/21/2025 |
| Reiterates | Citizens Capital Markets: Market Outperform to Market Outperform | 2/21/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/21/2025 |
Related Tickers
ANAB AnaptysBio, Inc.
20.55
+7.82%
DNLI Denali Therapeutics Inc.
12.74
+1.51%
CGEM Cullinan Therapeutics, Inc.
7.89
+3.68%
SYRE Spyre Therapeutics, Inc.
12.67
+2.01%
DYN Dyne Therapeutics, Inc.
8.17
+4.34%
SWTX SpringWorks Therapeutics, Inc.
37.92
+0.48%
EWTX Edgewise Therapeutics, Inc.
13.45
+3.22%
XNCR Xencor, Inc.
9.70
+1.89%
IDYA IDEAYA Biosciences, Inc.
17.08
+5.56%
AKRO Akero Therapeutics, Inc.
37.63
+0.51%